Cohance Lifesciences

990.45
-7.70
(-0.77%)
Market Cap
38,185.90 Cr
EPS
10.52
PE Ratio
140.82
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,119.00
52 Week Low
930.30
PB Ratio
22.06
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,669.40
#1 4,01,288.80
34.91
#1 54,729.00
12.06
#1 10,980
-18.99
45.64
6,983.50
1,84,182.10
84.72
9,360.00
0.89
2,117
23.05
71.05
1,491.70
1,20,211.20
23.42
28,409.50
7.12
5,291
30.28
46.52
3,353.70
1,12,445.10
59.27
11,539.40
11.59
1,911
10.91
58.97
1,269.40
1,07,142.20
#1 19.10
33,741.20
12.36
5,725
21.14
43.20
2,526.60
1,00,363.20
52.47
12,207.40
19.57
1,925
-10.91
66.43
978.45
98,932.90
21.08
22,573.80
13.82
3,977
-0.19
54.92
1,914.20
87,781.40
26.63
22,192.10
#1 19.94
3,024
#1 112.49
39.93
34,390.00
72,587.60
51.61
6,409.15
10.80
1,417
27.83
61.09
1,142.60
66,658.60
19.23
31,378.10
17.55
3,366
-0.50
48.79

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
-19.72 %
Net Income Growth
-26.99 %
Cash Flow Change
-21.59 %
ROE
-38.23 %
ROCE
-39.27 %
EBITDA Margin (Avg.)
-6.12 %

Quarterly Financial Results

Quarterly Financials
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
251
217
282
190
211
254
247
296
281
293
324
456
381
350
289
367
381
358
251
234
270
249
272
323
413
Expenses
129
95
147
99
108
126
140
138
166
149
179
206
207
188
179
207
198
181
133
154
180
151
154
189
329
EBITDA
122
122
135
91
103
128
107
158
116
144
144
251
174
162
111
160
183
178
118
80
90
98
118
133
84
Operating Profit %
49 %
52 %
46 %
45 %
41 %
47 %
41 %
50 %
36 %
43 %
40 %
48 %
43 %
45 %
36 %
41 %
47 %
48 %
42 %
30 %
29 %
35 %
40 %
38 %
18 %
Depreciation
6
6
6
6
7
7
8
9
8
9
9
11
10
12
12
12
12
13
12
13
17
13
17
20
27
Interest
2
4
4
8
7
3
3
2
2
2
1
1
2
2
0
1
5
1
1
2
2
2
2
3
6
Profit Before Tax
115
113
125
78
89
118
97
148
106
133
134
240
161
149
99
146
166
164
105
66
71
83
100
110
52
Tax
40
21
32
20
15
26
23
34
22
28
37
79
70
41
26
38
42
43
26
19
18
22
18
26
13
Net Profit
75
92
93
58
74
92
74
114
83
105
97
160
92
108
72
108
124
121
80
47
53
61
82
83
39
EPS in ₹
5.88
7.22
3.65
4.55
5.83
3.60
2.91
4.46
3.27
4.13
3.81
6.29
3.60
4.22
2.83
4.23
4.87
4.74
3.13
1.84
2.10
2.39
3.23
3.26
1.65

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
2025
Total Assets
783
1,173
1,475
1,830
1,966
2,254
3,032
Fixed Assets
271
357
441
534
663
670
1,314
Current Assets
390
392
565
1,128
1,011
1,263
853
Capital Work in Progress
111
102
96
30
165
179
255
Investments
7
338
542
598
536
905
167
Other Assets
394
376
395
667
601
501
35
Total Liabilities
783
1,173
1,475
1,830
1,966
2,254
3,032
Current Liabilities
158
200
220
210
159
107
365
Non Current Liabilities
35
128
74
92
72
97
826
Total Equity
590
845
1,181
1,527
1,735
2,051
1,697
Reserve & Surplus
578
832
1,155
1,502
1,710
2,025
1,671
Share Capital
13
13
26
26
26
26
26

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
11
1
-5
37
20
-18
Investing Activities
-66
-414
-311
-136
-195
-362
Operating Activities
50
407
383
330
457
359
Financing Activities
26
7
-76
-157
-242
-14

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
May 2025
Promoter
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
50.10 %
50.10 %
50.10 %
50.10 %
50.10 %
66.41 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.01 %
10.14 %
9.54 %
9.80 %
10.70 %
10.84 %
11.05 %
7.38 %
DIIs
4.30 %
4.47 %
4.94 %
5.24 %
5.91 %
6.32 %
10.52 %
11.35 %
11.43 %
9.23 %
14.14 %
15.94 %
17.24 %
17.42 %
16.94 %
16.68 %
16.60 %
11.02 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
20.87 %
19.86 %
19.21 %
18.38 %
17.07 %
16.86 %
14.69 %
14.01 %
12.76 %
12.80 %
11.76 %
10.87 %
10.51 %
10.08 %
9.75 %
9.81 %
9.68 %
6.63 %
Others
14.84 %
15.68 %
15.86 %
16.38 %
17.02 %
16.82 %
14.78 %
14.64 %
15.81 %
17.97 %
4.08 %
3.04 %
12.59 %
12.59 %
12.50 %
12.56 %
12.55 %
8.55 %
No of Share Holders
75,207
92,534
96,532
86,447
85,725
86,088
82,577
79,412
72,885
72,167
73,715
70,052
68,932
65,777
69,337
84,210
86,325
88,658

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 5 2 5 6 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 1.01 0.32 1.06 0.89 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
19 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
19 Sept 2025 1,002.10 985.75
13 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Aug 2025 944.05 985.75
28 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 May 2025 1,113.40 1,107.75
07 May 2025 CHANGE OF NAME Change Of Name
NA
07 May 2025 1,081.70 1,081.70
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 1,167.40 1,045.70
28 Nov 2024 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
28 Nov 2024 1,278.00 1,274.90
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 1,177.00 1,203.75
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 848.75 972.55
15 Dec 2023 ANNUAL GENERAL MEETING Annual General Meeting
NA
15 Dec 2023 556.60 702.10
12 Sept 2022 DIVIDEND Dividend
₹ 5.00 /share
09 Sept 2022 491.25 476.05
12 Sept 2022 DIVIDEND Dividend
₹ 1.00 /share
09 Sept 2022 491.25 476.05
17 May 2022 DIVIDEND Dividend
₹ 1.00 /share
13 May 2022 563.95 516.30
17 May 2022 DIVIDEND Dividend
₹ 1.00 /share
13 May 2022 563.95 516.30
16 Feb 2022 DIVIDEND Dividend
₹ 2.00 /share
15 Feb 2022 569.60 547.90
16 Feb 2022 DIVIDEND Dividend
₹ 1.00 /share
15 Feb 2022 569.60 547.90
17 Aug 2021 DIVIDEND Dividend
₹ 1.00 /share
13 Aug 2021 496.45 554.30
18 Feb 2021 DIVIDEND Dividend
₹ 1.00 /share
17 Feb 2021 507.45 497.10
28 Sept 2020 BONUS Bonus
1:1
25 Sept 2020 387.25 400.45

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20187 days ago
Closure of Trading WindowJun 27, 2025
Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ending June 30 2025Jun 27, 2025
Disclosure Under Regulation 30 Of The SEBI Listing RegulationsJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 20, 2025
Disclosure Regarding Sale Of Assets Of Clinical Research And Bio-Analytical Studies Site (CR Bio) Of The Company.Jun 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMay 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 28, 2025
Financial Results For Period Ended March 31 2025May 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 28, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
General AnnouncementMay 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Change In The Name And Trading SymbolMay 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 13, 2025
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.May 12, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.May 12, 2025
Announcement under Regulation 30 (LODR)-AllotmentMay 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 07, 2025
Announcement under Regulation 30 (LODR)-Change of Company NameMay 07, 2025
Intimation Of Effective Date Of Merger And Record DateApr 25, 2025
Update On MergerApr 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Cautionary Email Received From The Stock ExchangeApr 02, 2025
Cautionary Email Received From The Stock ExchangeApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 28, 2025
Update On MergerMar 27, 2025
Closure of Trading WindowMar 26, 2025
Board Meeting Intimation for To Consider And Approve The Financial Results For The Period Ended March 31 2025Mar 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Integrated Filing (Financial)Feb 12, 2025

Technical Indicators

RSI(14)
Neutral
46.20
ATR(14)
Less Volatile
36.28
STOCH(9,6)
Neutral
68.04
STOCH RSI(14)
Neutral
69.23
MACD(12,26)
Bullish
5.99
ADX(14)
Weak Trend
20.51
UO(9)
Bearish
57.61
ROC(12)
Uptrend But Slowing Down
0.81
WillR(14)
Neutral
-49.71

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
DSP Healthcare Fund Direct - Growth
0.00%
-2489539
-8.81%
-9.72%
DSP ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-1910066
-1.18%
-1.31%
Invesco India Contra Fund Direct-Growth
0.00%
-1907071
-1.09%
-1.20%
DSP Flexi Cap Fund Direct Plan-Growth
0.00%
-1830535
-1.62%
-1.82%
HSBC Small Cap Fund Direct-Growth
0.00%
-1747867
-1.14%
-1.77%
Axis Small Cap Fund Direct-Growth
0.00%
-1731442
-0.72%
-0.65%
360 ONE Focused Fund Direct-Growth
0.00%
-1486815
-2.11%
-2.28%
DSP Equity Opportunities Fund Direct Plan-Growth
0.00%
-1467138
-1.02%
-1.16%
Canara Robeco Small Cap Fund Direct - Growth
0.00%
-1239108
-1.05%
-1.23%
DSP Aggressive Hybrid Fund Direct-Growth
0.00%
-1157877
-1.09%
-1.22%
Invesco India Focused Fund Direct - Growth
0.00%
-1025381
-2.70%
-3.16%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-995888
-3.88%
-3.81%
Invesco India Smallcap Fund Direct - Growth
0.00%
-939460
-1.44%
-1.72%
JM Flexicap Fund Direct Plan-Growth
0.00%
-686549
-1.22%
-1.39%
DSP Top 100 Equity Direct Plan-Growth
0.00%
-593188
-1.03%
-1.20%
DSP Focus Direct Plan-Growth
0.00%
-589110
-2.40%
-2.71%
HDFC Manufacturing Fund Direct - Growth
0.00%
-560510
-0.49%
0.00%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
-540000
-1.53%
-1.67%
Axis India Manufacturing Fund Direct-Growth
0.00%
-386738
-0.73%
-0.82%
360 ONE FlexiCap Fund Direct - Growth
0.00%
-367638
-2.18%
-2.60%
DSP Multicap Fund Direct - Growth
0.00%
-320840
-1.49%
-1.76%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-318031
-1.95%
-1.49%
Invesco India Multicap Fund Direct-Growth
0.00%
-312317
-0.82%
-0.94%
Mirae Asset Small Cap Fund Direct-Growth
0.00%
-256417
-1.70%
-1.88%
ITI Small Cap Fund Direct-Growth
0.00%
-253200
-1.06%
-1.26%

About Cohance Lifesciences

Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Chairperson NameVIVEK SHARMA